Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of alzheimer's disease

This publication has 14 references indexed in Scilit:

• Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease*
  Clinical Pharmacology & Therapeutics, 1995
• Age-specific incidence of Alzheimer's disease in a community population
  JAMA, 1995
• Tacrine
  The Lancet, 1995
• The US economic and social costs of Alzheimer's disease revisited.
  American Journal of Public Health, 1994
• Incidence of dementia and probable Alzheimer's disease in a general population
  Neurology, 1993
• Effects of the Novel Acetylcholinesterase Inhibitor SDZ ENA 713 on Sleep in Man
  Neuropsychopharmacology, 1993
• Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study
  Neurology, 1992
• Pharmacologic and Clinicopharmacologic Properties of SDZ ENA 713, a Centrally Selective Acetylcholinesterase Inhibitor
  Annals of the New York Academy of Sciences, 1991
• THE CHOLINERGIC HYPOTHESIS—TEN YEARS ON
  British Medical Bulletin, 1986
• Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
  Science, 1982